Chemogenomic analysis identifies macbecin ii as a compound specific for smad4-negative colon cancer cells: Research article

Christine Kaiser, Nathalie Meurice, Irma M. Gonzales, Shilpi Arora, Christian Beaudry, Kristen M. Bisanz, Alexander C. Robeson, Joachim Petit, David O. Azorsa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The tumor suppressor gene, SMAD4, is mutated in approximately 30% of colon cancers. To identify compounds with enhanced potency on cells with a SMAD4-negative context, we combined genomic and cheminformatic analyses of publicly available data relating to the colon cancer cell lines within the NCI60 panel. Two groups of cell lines were identified with either wild-type or negative SMAD4 status. A cheminformatic analysis of the NCI60 screening data was carried out, which led to the identification of 14 compounds that preferentially inhibited cell growth of the SMAD4-negative cell lines. Using cell viability assays, the effect of these compounds was validated on four colon cancer cell lines: HCT-116 and HCT-15 (SMAD4-expressing), and HT-29 and COLO-205 (SMAD4-negative). Our data identified Macbecin II, a hydroquinone ansamycin antibiotic, as having increased potency in the SMAD4-negative cells compared to SMAD4 wild-type cells. In addition, we showed that silencing of SMAD4 using siRNA in HCT-116 enhanced Macbecin II potency. Our results demonstrate that Macbecin II is specifically active in colon cancer cells having a SMAD4-negative background and thus is a potential candidate for further investigation in a drug discovery perspective.

Original languageEnglish (US)
Pages (from-to)360-368
Number of pages9
JournalChemical Biology and Drug Design
Volume75
Issue number4
DOIs
StatePublished - Apr 2010
Externally publishedYes

Fingerprint

Colonic Neoplasms
Cells
Cell Line
Research
Rifabutin
Drug Discovery
Tumor Suppressor Genes
Small Interfering RNA
Cell growth
Cell Survival
Tumors
Assays
Screening
Anti-Bacterial Agents
Genes
Growth
macbecin II

Keywords

  • Cheminformatics
  • Colon cancer
  • Macbecin II
  • NCI-60
  • SMAD4

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Cite this

Chemogenomic analysis identifies macbecin ii as a compound specific for smad4-negative colon cancer cells : Research article. / Kaiser, Christine; Meurice, Nathalie; Gonzales, Irma M.; Arora, Shilpi; Beaudry, Christian; Bisanz, Kristen M.; Robeson, Alexander C.; Petit, Joachim; Azorsa, David O.

In: Chemical Biology and Drug Design, Vol. 75, No. 4, 04.2010, p. 360-368.

Research output: Contribution to journalArticle

Kaiser, C, Meurice, N, Gonzales, IM, Arora, S, Beaudry, C, Bisanz, KM, Robeson, AC, Petit, J & Azorsa, DO 2010, 'Chemogenomic analysis identifies macbecin ii as a compound specific for smad4-negative colon cancer cells: Research article', Chemical Biology and Drug Design, vol. 75, no. 4, pp. 360-368. https://doi.org/10.1111/j.1747-0285.2010.00949.x
Kaiser, Christine ; Meurice, Nathalie ; Gonzales, Irma M. ; Arora, Shilpi ; Beaudry, Christian ; Bisanz, Kristen M. ; Robeson, Alexander C. ; Petit, Joachim ; Azorsa, David O. / Chemogenomic analysis identifies macbecin ii as a compound specific for smad4-negative colon cancer cells : Research article. In: Chemical Biology and Drug Design. 2010 ; Vol. 75, No. 4. pp. 360-368.
@article{cfd6af687a2c4cbfad98c88332f68e3d,
title = "Chemogenomic analysis identifies macbecin ii as a compound specific for smad4-negative colon cancer cells: Research article",
abstract = "The tumor suppressor gene, SMAD4, is mutated in approximately 30{\%} of colon cancers. To identify compounds with enhanced potency on cells with a SMAD4-negative context, we combined genomic and cheminformatic analyses of publicly available data relating to the colon cancer cell lines within the NCI60 panel. Two groups of cell lines were identified with either wild-type or negative SMAD4 status. A cheminformatic analysis of the NCI60 screening data was carried out, which led to the identification of 14 compounds that preferentially inhibited cell growth of the SMAD4-negative cell lines. Using cell viability assays, the effect of these compounds was validated on four colon cancer cell lines: HCT-116 and HCT-15 (SMAD4-expressing), and HT-29 and COLO-205 (SMAD4-negative). Our data identified Macbecin II, a hydroquinone ansamycin antibiotic, as having increased potency in the SMAD4-negative cells compared to SMAD4 wild-type cells. In addition, we showed that silencing of SMAD4 using siRNA in HCT-116 enhanced Macbecin II potency. Our results demonstrate that Macbecin II is specifically active in colon cancer cells having a SMAD4-negative background and thus is a potential candidate for further investigation in a drug discovery perspective.",
keywords = "Cheminformatics, Colon cancer, Macbecin II, NCI-60, SMAD4",
author = "Christine Kaiser and Nathalie Meurice and Gonzales, {Irma M.} and Shilpi Arora and Christian Beaudry and Bisanz, {Kristen M.} and Robeson, {Alexander C.} and Joachim Petit and Azorsa, {David O.}",
year = "2010",
month = "4",
doi = "10.1111/j.1747-0285.2010.00949.x",
language = "English (US)",
volume = "75",
pages = "360--368",
journal = "Chemical Biology and Drug Design",
issn = "1747-0277",
publisher = "Blackwell",
number = "4",

}

TY - JOUR

T1 - Chemogenomic analysis identifies macbecin ii as a compound specific for smad4-negative colon cancer cells

T2 - Research article

AU - Kaiser, Christine

AU - Meurice, Nathalie

AU - Gonzales, Irma M.

AU - Arora, Shilpi

AU - Beaudry, Christian

AU - Bisanz, Kristen M.

AU - Robeson, Alexander C.

AU - Petit, Joachim

AU - Azorsa, David O.

PY - 2010/4

Y1 - 2010/4

N2 - The tumor suppressor gene, SMAD4, is mutated in approximately 30% of colon cancers. To identify compounds with enhanced potency on cells with a SMAD4-negative context, we combined genomic and cheminformatic analyses of publicly available data relating to the colon cancer cell lines within the NCI60 panel. Two groups of cell lines were identified with either wild-type or negative SMAD4 status. A cheminformatic analysis of the NCI60 screening data was carried out, which led to the identification of 14 compounds that preferentially inhibited cell growth of the SMAD4-negative cell lines. Using cell viability assays, the effect of these compounds was validated on four colon cancer cell lines: HCT-116 and HCT-15 (SMAD4-expressing), and HT-29 and COLO-205 (SMAD4-negative). Our data identified Macbecin II, a hydroquinone ansamycin antibiotic, as having increased potency in the SMAD4-negative cells compared to SMAD4 wild-type cells. In addition, we showed that silencing of SMAD4 using siRNA in HCT-116 enhanced Macbecin II potency. Our results demonstrate that Macbecin II is specifically active in colon cancer cells having a SMAD4-negative background and thus is a potential candidate for further investigation in a drug discovery perspective.

AB - The tumor suppressor gene, SMAD4, is mutated in approximately 30% of colon cancers. To identify compounds with enhanced potency on cells with a SMAD4-negative context, we combined genomic and cheminformatic analyses of publicly available data relating to the colon cancer cell lines within the NCI60 panel. Two groups of cell lines were identified with either wild-type or negative SMAD4 status. A cheminformatic analysis of the NCI60 screening data was carried out, which led to the identification of 14 compounds that preferentially inhibited cell growth of the SMAD4-negative cell lines. Using cell viability assays, the effect of these compounds was validated on four colon cancer cell lines: HCT-116 and HCT-15 (SMAD4-expressing), and HT-29 and COLO-205 (SMAD4-negative). Our data identified Macbecin II, a hydroquinone ansamycin antibiotic, as having increased potency in the SMAD4-negative cells compared to SMAD4 wild-type cells. In addition, we showed that silencing of SMAD4 using siRNA in HCT-116 enhanced Macbecin II potency. Our results demonstrate that Macbecin II is specifically active in colon cancer cells having a SMAD4-negative background and thus is a potential candidate for further investigation in a drug discovery perspective.

KW - Cheminformatics

KW - Colon cancer

KW - Macbecin II

KW - NCI-60

KW - SMAD4

UR - http://www.scopus.com/inward/record.url?scp=77449129655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449129655&partnerID=8YFLogxK

U2 - 10.1111/j.1747-0285.2010.00949.x

DO - 10.1111/j.1747-0285.2010.00949.x

M3 - Article

C2 - 20331650

AN - SCOPUS:77449129655

VL - 75

SP - 360

EP - 368

JO - Chemical Biology and Drug Design

JF - Chemical Biology and Drug Design

SN - 1747-0277

IS - 4

ER -